Review

compound 10a (MedChemExpress)

Name: compound 10a
Brand: MedChemExpress
Rating: 93 (2 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress compound 10a
Compound 10a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 10a/product/MedChemExpress
Average 93 stars, based on 2 article reviews

compound 10a - by Bioz Stars, 2026-02

93/100 stars

Images

Image Search Results

Desensitization of PI(4,5)P 2 hydrolysis and G protein activation, and recruitment of β-arrestin-1/2 and GRK2/3/6 to activated OXTR in primary neuronal cultures (A) Summary graph (bottom) of normalized BRET showing the time course of PI(4,5)P 2 hydrolysis downstream of OXTR activation by 200 nM TGOT (time of application is indicated by an arrow). Schematic (top) shows the BRET configuration with nanoLuc-PH-PLCδ and HaloTag-CAAX. Normalized BRET is reduced rapidly with TGOT application in control (black) followed by quick recovery suggesting desensitization ( n = 3). Gα q inhibitor UBO-QIC (1 μM, blue) abolished the response, whereas Gβγ inhibitor Gallein (40 μM, magenta) had no effect (n = 3–5 per group). (B) Summary graph (bottom) of ΔBRET showing the time course of G protein activation downstream of OXTR activation by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing nanoLuc-Gγ, Gβ, and Gα q along with GRK2-HaloTag. BRET is rapidly increased with TGOT application followed by quick recovery suggesting desensitization at the G protein level (n = 3). (C) Summary graph (bottom) of ΔBRET showing the time course of recruitment of β-arrestin-1 and β-arrestin-2 to neuronal OXTR activated by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing OXTR-nanoLuc and β-arrestin-1 (blue) or β-arrestin-2 (magenta). BRET is increased with TGOT application suggesting recruitment of both β-arrestins to neuronal OXTR (n = 3–5 per group). (D) Summary graph (bottom) of ΔBRET time course shows that GRK2, GRK3, and GRK6 (but not GRK5) are recruited to neuronal OXTR activated by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing OXTR-nanoLuc and GRK2-HaloTag (red), GRK3-HaloTag (blue), GRK5-HaloTag (gray), or GRK6-HaloTag (magenta) (n = 4 per group). The data in graphs are shown as mean ± SEM.

Journal: iScience

Article Title: Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons

doi: 10.1016/j.isci.2024.110047

Figure Lengend Snippet: Desensitization of PI(4,5)P 2 hydrolysis and G protein activation, and recruitment of β-arrestin-1/2 and GRK2/3/6 to activated OXTR in primary neuronal cultures (A) Summary graph (bottom) of normalized BRET showing the time course of PI(4,5)P 2 hydrolysis downstream of OXTR activation by 200 nM TGOT (time of application is indicated by an arrow). Schematic (top) shows the BRET configuration with nanoLuc-PH-PLCδ and HaloTag-CAAX. Normalized BRET is reduced rapidly with TGOT application in control (black) followed by quick recovery suggesting desensitization ( n = 3). Gα q inhibitor UBO-QIC (1 μM, blue) abolished the response, whereas Gβγ inhibitor Gallein (40 μM, magenta) had no effect (n = 3–5 per group). (B) Summary graph (bottom) of ΔBRET showing the time course of G protein activation downstream of OXTR activation by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing nanoLuc-Gγ, Gβ, and Gα q along with GRK2-HaloTag. BRET is rapidly increased with TGOT application followed by quick recovery suggesting desensitization at the G protein level (n = 3). (C) Summary graph (bottom) of ΔBRET showing the time course of recruitment of β-arrestin-1 and β-arrestin-2 to neuronal OXTR activated by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing OXTR-nanoLuc and β-arrestin-1 (blue) or β-arrestin-2 (magenta). BRET is increased with TGOT application suggesting recruitment of both β-arrestins to neuronal OXTR (n = 3–5 per group). (D) Summary graph (bottom) of ΔBRET time course shows that GRK2, GRK3, and GRK6 (but not GRK5) are recruited to neuronal OXTR activated by 200 nM TGOT. Schematic (top) shows the BRET configuration with neurons expressing OXTR-nanoLuc and GRK2-HaloTag (red), GRK3-HaloTag (blue), GRK5-HaloTag (gray), or GRK6-HaloTag (magenta) (n = 4 per group). The data in graphs are shown as mean ± SEM.

Article Snippet: Oxytocin (1910, Tocris), (Thr⁴,Gly⁷)-Oxytocin (TGOT) (4013837, Bachem), SR49059 (17972, Cayman Chemical, (d(CH 2 ) 5 1 ,Tyr(Me) 2 ,Arg 8 )-Vasopressin (3377,Tocris), FR900359 (UBO-QIC) (33666, Cayman Chemical) Tetrodotoxin (14964, Cayman Chemical) NBQX (14914, Cayman Chemical), Picrotoxin (P1675-5G, Sigma), Gallein (3090,Tocris), CMPD101 (26808, Cayman Chemical), Barbadin (HY-119706, MedChemExpress), GRK6-IN-1 (HY-142812, MedChemExpress), and GRK6-IN-2 (HY-142817, MedChemExpress) were purchased from vendors as indicated.

Techniques: Activation Assay, Control, Expressing

GRK2/3/6 are required while β-arrestins are redundant for neuronal OXTR desensitization (A) Whole-cell recordings of sIPSC from dorsal LS neurons of β-arrestin-1 KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces for baseline (black), first response (blue), and second response (magenta) (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (B) Whole-cell recordings of sIPSC from dorsal LS neurons of β-arrestin-2 KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (C) Schematic showing the strategy for CRISPR/Cas9-based KO of β-arrestin-1 in the LS of constitutive β-arrestin-2 KO mice. Inset shows expression of GFP from AAV GFP-Cre and AAV gRNA-Syn-GFP in the LS. Scale bar: 400 μm. (D) Immunohistochemical confirmation of CRISPR/Cas9-induced depletion of β-arrestin-1 in the LS. Sections were stained with antibody against GFP or β-arrestin-1 in control and injected animals. Scale bar: 100 μm. (E) Immunoblots on LS lysates from WT, β-arrestin-1 KO ( Arrb1 −/− ), β-arrestin-2 KO ( Arrb2 −/− ), and CRISPR/Cas9-induced β-arrestin-1 KO ( gArrb1 ) in β-arrestin-2 KO mice. Blots were stained with antibodies against β-arrestin-1, β-arrestin-2, and β-actin. (F) Whole-cell recordings of sIPSC from dorsal LS neurons of double β-arrestin KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (G) Whole-cell recordings of sIPSC from dorsal LS neurons in control condition (brown) and in the presence of CMPD101 (50 μM) and GRK6-IN-2 (50 μM) (blue). The summary graph of the time course of response to two applications of 200 nM TGOT for 1 min each separated by 15 min is shown (bottom). There is strong response to the second TGOT application in the presence of CMPD101 and GRK6-IN-2, indicating suppression of OXTR desensitization. Sample traces for CMPD101+GRK6-IN-2 condition are shown above the graph. (H) Bar graphs with baseline, first peak response, and second peak response in WT, β-arrestin-1 KO ( Arrb1 −/− ), β-arrestin-2 KO ( Arrb2 −/− ), double β-arrestin KO ( Arrb2 −/− + gArrb1 ), and GRK2/3/6 inhibition (CMPD101 + GRK6-IN-2). sIPSC frequency (Hz) WT: baseline, 2.920 ± 0.413; 1 st response, 13.100 ± 1.538; 2 nd response, 3.095 ± 0.314; n = 7 cells, 5 mice. sIPSC frequency (Hz) Arrb1 −/− : baseline, 4.136 ± 0.917; 1 st response, 12.590 ± 2.155; 2 nd response, 4.510 ± 1.003; n = 7 cells, 4 mice. sIPSC frequency (Hz) Arrb2 −/− : baseline, 2.813 ± 0.404; 1 st response, 13.150 ± 1.410; 2 nd response, 3.020 ± 0.277; n = 6 cells, 3 mice. sIPSC frequency (Hz) Arrb2 −/− + gArrb1 : baseline, 3.055 ± 0.486; 1 st response, 8.880 ± 1.342; 2 nd response, 3.927 ± 0.468; n = 10 cells, 6 mice. sIPSC frequency (Hz) CMPD101 + GRK6-IN-2: baseline, 2.600 ± 0.491; 1 st response, 15.410 ± 0.946; 2 nd response, 10.680 ± 1.506; n = 7 cells, 5 mice. The data in graphs are shown as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, Repeated measures two-way ANOVA with post-hoc Tukey’s multiple comparisons test.

Journal: iScience

Article Title: Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons

doi: 10.1016/j.isci.2024.110047

Figure Lengend Snippet: GRK2/3/6 are required while β-arrestins are redundant for neuronal OXTR desensitization (A) Whole-cell recordings of sIPSC from dorsal LS neurons of β-arrestin-1 KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces for baseline (black), first response (blue), and second response (magenta) (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (B) Whole-cell recordings of sIPSC from dorsal LS neurons of β-arrestin-2 KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (C) Schematic showing the strategy for CRISPR/Cas9-based KO of β-arrestin-1 in the LS of constitutive β-arrestin-2 KO mice. Inset shows expression of GFP from AAV GFP-Cre and AAV gRNA-Syn-GFP in the LS. Scale bar: 400 μm. (D) Immunohistochemical confirmation of CRISPR/Cas9-induced depletion of β-arrestin-1 in the LS. Sections were stained with antibody against GFP or β-arrestin-1 in control and injected animals. Scale bar: 100 μm. (E) Immunoblots on LS lysates from WT, β-arrestin-1 KO ( Arrb1 −/− ), β-arrestin-2 KO ( Arrb2 −/− ), and CRISPR/Cas9-induced β-arrestin-1 KO ( gArrb1 ) in β-arrestin-2 KO mice. Blots were stained with antibodies against β-arrestin-1, β-arrestin-2, and β-actin. (F) Whole-cell recordings of sIPSC from dorsal LS neurons of double β-arrestin KO mice showing response to two applications of 200 nM TGOT for 1 min each separated by 15 min. Sample traces (top) and summary graph of time course (bottom) are shown. The lack of robust second response compared to first indicates intact OXTR desensitization. (G) Whole-cell recordings of sIPSC from dorsal LS neurons in control condition (brown) and in the presence of CMPD101 (50 μM) and GRK6-IN-2 (50 μM) (blue). The summary graph of the time course of response to two applications of 200 nM TGOT for 1 min each separated by 15 min is shown (bottom). There is strong response to the second TGOT application in the presence of CMPD101 and GRK6-IN-2, indicating suppression of OXTR desensitization. Sample traces for CMPD101+GRK6-IN-2 condition are shown above the graph. (H) Bar graphs with baseline, first peak response, and second peak response in WT, β-arrestin-1 KO ( Arrb1 −/− ), β-arrestin-2 KO ( Arrb2 −/− ), double β-arrestin KO ( Arrb2 −/− + gArrb1 ), and GRK2/3/6 inhibition (CMPD101 + GRK6-IN-2). sIPSC frequency (Hz) WT: baseline, 2.920 ± 0.413; 1 st response, 13.100 ± 1.538; 2 nd response, 3.095 ± 0.314; n = 7 cells, 5 mice. sIPSC frequency (Hz) Arrb1 −/− : baseline, 4.136 ± 0.917; 1 st response, 12.590 ± 2.155; 2 nd response, 4.510 ± 1.003; n = 7 cells, 4 mice. sIPSC frequency (Hz) Arrb2 −/− : baseline, 2.813 ± 0.404; 1 st response, 13.150 ± 1.410; 2 nd response, 3.020 ± 0.277; n = 6 cells, 3 mice. sIPSC frequency (Hz) Arrb2 −/− + gArrb1 : baseline, 3.055 ± 0.486; 1 st response, 8.880 ± 1.342; 2 nd response, 3.927 ± 0.468; n = 10 cells, 6 mice. sIPSC frequency (Hz) CMPD101 + GRK6-IN-2: baseline, 2.600 ± 0.491; 1 st response, 15.410 ± 0.946; 2 nd response, 10.680 ± 1.506; n = 7 cells, 5 mice. The data in graphs are shown as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, Repeated measures two-way ANOVA with post-hoc Tukey’s multiple comparisons test.

Techniques: CRISPR, Expressing, Immunohistochemical staining, Staining, Control, Injection, Western Blot, Inhibition

Molecular mechanisms underlying agonist-induced internalization and trafficking of neuronal OXTR (A) Schematic depicting BRET assays for tracking OXTR internalization and trafficking in primary neuronal cultures. BRET was configured with OXTR-nanoLuc along with HaloTag-CAAX (for cell membrane localization), HaloTag-2xFYVE (early endosome), HaloTag-Rab11 (recycling endosome), HaloTag-Rab5 (Rab5 compartment), and HaloTag-Rab21 (Rab21 compartment). (B) Summary graph of normalized BRET showing the time course of neuronal OXTR internalization (HaloTag-CAAX), trafficking to early endosomes (HaloTag-2xFYVE) and moving into recycling endosomes (HaloTag-Rab11) following application of 200 nM TGOT (time of application is indicated by an arrow) (n = 3–9 per group). (C) Summary graph of normalized BRET showing the time course of neuronal OXTR trafficking to Rab5-but not Rab21-containing endosomes following application of 200 nM TGOT (n = 3–5 per group). (D) Trafficking of neuronal OXTR to early endosomes in response to 200 nM TGOT was impaired with expression of dominant negative Rab5 (Rab5 DN). Summary graph of the time course (left) of normalized BRET with OXTR-nanoLuc and HaloTag-2xFYVE. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. Control, 2.052 ± 0.128; Rab5 DN, 1.043 ± 0.041; n = 6–8 per group. (E) Internalization of neuronal OXTR in response to 200 nM TGOT was not affected with expression of dominant negative Rab5 (Rab5 DN). Summary graph of the time course (left) of normalized BRET with OXTR-nanoLuc and HaloTag-CAAX is shown. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. Control, 0.383 ± 0.023; Rab5 DN, 0.386 ± 0.017; n = 5 per group. (F) Summary graph (left) of normalized BRET showing the time course of neuronal OXTR internalization in the presence of vehicle (DMSO), Barbadin, CMPD101, GRK6-IN-1, GRK6-IN-2, and a mix of CMPD101 and GRK6-IN-1 (CMPD101+GRK6-IN-1) or a mix of CMPD101 and GRK6-IN-2 (CMPD101+GRK6-IN-2). BRET was configured with OXTR-nanoLuc and HaloTag-CAAX. The internalization was impaired in the presence of a mix of CMPD101 and GRK6-IN-2 but not with Barbadin, CMPD101, or GRK6-IN-2 alone. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. DMSO, 0.348 ± 0.027; CMPD101, 0.409 ± 0.046; GRK6-IN-1, 0.396 ± 0.029; GRK6-IN-2, 0.445 ± 0.017; CMPD101 + GRK6-IN-1, 0.703 ± 0.019; CMPD101 +GRK6-IN-2, 0.711 ± 0.027; Barbadin, 0.328 ± 0.022; n = 3–5 per group. The data in graphs are shown as mean ± SEM. ∗∗∗∗p < 0.0001, unpaired Student’s t test (D and E) or one-way ANOVA with post-hoc Dunnett’s test (F).

Journal: iScience

Article Title: Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons

doi: 10.1016/j.isci.2024.110047

Figure Lengend Snippet: Molecular mechanisms underlying agonist-induced internalization and trafficking of neuronal OXTR (A) Schematic depicting BRET assays for tracking OXTR internalization and trafficking in primary neuronal cultures. BRET was configured with OXTR-nanoLuc along with HaloTag-CAAX (for cell membrane localization), HaloTag-2xFYVE (early endosome), HaloTag-Rab11 (recycling endosome), HaloTag-Rab5 (Rab5 compartment), and HaloTag-Rab21 (Rab21 compartment). (B) Summary graph of normalized BRET showing the time course of neuronal OXTR internalization (HaloTag-CAAX), trafficking to early endosomes (HaloTag-2xFYVE) and moving into recycling endosomes (HaloTag-Rab11) following application of 200 nM TGOT (time of application is indicated by an arrow) (n = 3–9 per group). (C) Summary graph of normalized BRET showing the time course of neuronal OXTR trafficking to Rab5-but not Rab21-containing endosomes following application of 200 nM TGOT (n = 3–5 per group). (D) Trafficking of neuronal OXTR to early endosomes in response to 200 nM TGOT was impaired with expression of dominant negative Rab5 (Rab5 DN). Summary graph of the time course (left) of normalized BRET with OXTR-nanoLuc and HaloTag-2xFYVE. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. Control, 2.052 ± 0.128; Rab5 DN, 1.043 ± 0.041; n = 6–8 per group. (E) Internalization of neuronal OXTR in response to 200 nM TGOT was not affected with expression of dominant negative Rab5 (Rab5 DN). Summary graph of the time course (left) of normalized BRET with OXTR-nanoLuc and HaloTag-CAAX is shown. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. Control, 0.383 ± 0.023; Rab5 DN, 0.386 ± 0.017; n = 5 per group. (F) Summary graph (left) of normalized BRET showing the time course of neuronal OXTR internalization in the presence of vehicle (DMSO), Barbadin, CMPD101, GRK6-IN-1, GRK6-IN-2, and a mix of CMPD101 and GRK6-IN-1 (CMPD101+GRK6-IN-1) or a mix of CMPD101 and GRK6-IN-2 (CMPD101+GRK6-IN-2). BRET was configured with OXTR-nanoLuc and HaloTag-CAAX. The internalization was impaired in the presence of a mix of CMPD101 and GRK6-IN-2 but not with Barbadin, CMPD101, or GRK6-IN-2 alone. The bar graph of the averaged normalized BRET response for the last 5 min is shown on right. DMSO, 0.348 ± 0.027; CMPD101, 0.409 ± 0.046; GRK6-IN-1, 0.396 ± 0.029; GRK6-IN-2, 0.445 ± 0.017; CMPD101 + GRK6-IN-1, 0.703 ± 0.019; CMPD101 +GRK6-IN-2, 0.711 ± 0.027; Barbadin, 0.328 ± 0.022; n = 3–5 per group. The data in graphs are shown as mean ± SEM. ∗∗∗∗p < 0.0001, unpaired Student’s t test (D and E) or one-way ANOVA with post-hoc Dunnett’s test (F).

Techniques: Membrane, Expressing, Dominant Negative Mutation, Control

Journal: iScience

Article Title: Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons

doi: 10.1016/j.isci.2024.110047

Figure Lengend Snippet:

Techniques: Virus, Plasmid Preparation, Recombinant, Sequencing, Software

Journal: iScience

Article Title: Robust GRK2/3/6-dependent desensitization of oxytocin receptor in neurons

doi: 10.1016/j.isci.2024.110047

Figure Lengend Snippet:

Article Snippet: GRK6-IN-2 , MedChemExpress , Cat# HY-142817, CAS: 2677786-27-3.

Techniques: Virus, Plasmid Preparation, Recombinant, Sequencing, Software

Review

Structured Review

Images

Similar Products

Image Search Results